Heart failure in 2025: new insights, therapies, and clinical directions
Authors:
- Zifan ShenZSZifan Shen
- Pingjing ZhengPZPingjing Zheng
- Gaocheng GuGGGaocheng Gu
- Yang ZhangYZYang Zhang
- Zhangwei ChenZCZhangwei Chen
- Juying QianJQJuying Qian
Open Access
- 1 April 2026
- journal article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (4) , 412
Abstract
Heart failure (HF) remains a major cause of morbidity and mortality globally, affecting between 1% and 3% of the total population. Despite the great efficacy of guideline-directed medical therapy (GDMT), patients still face high rates of rehospitalization and mortality. In the past year, emerging research has brought multiple up-to-date insights into HF treatment and substantial new options for clinicians. This review synthesizes landmark research and clinical progress in 2025 concerning epidemiological trends, causes, risk factors and treatments, aiming to update the evolving landscape of HF treatment. Significant progress is noted in pharmacotherapy (e.g., finerenone, tirzepatide) and device-based therapies [e.g., preCARDIA, cardiac resynchronization therapy with defibrillator (CRT-D)]. The completion of large-scale clinical trials, such as the DAPA ACT HF-TIMI 68 trial and the VICTOR trial, has offered solid evidence for the evolution in clinical practice. The emergence of novel devices offers promising alternatives and supplements to conventional therapies as well. Additionally, cutting-edge therapies like stem cell therapy have also revealed promising clinical prospects. Despite continuous therapeutic advances, substantial unmet needs in treatment and management still present a great challenge, necessitating further research to discover novel and better therapeutic strategies. Hence, major large-scale clinical trials initiated in 2025 are synthesized and anticipated as well. In brief, this review provides a timely update to guide clinical practice and future investigation.Keywords
This publication has 51 references indexed in Scilit:
- Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implantsEuropean Journal of Heart Failure, 2021
- Incidence and Outcomes of Pneumonia in Patients With Heart FailureJACC, 2021
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureEuropean Journal of Heart Failure, 2021
- Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac Resynchronization Device TherapyJACC, 2019
- Trajectory of thirst intensity and distress from admission to 4-weeks follow up at home in patients with heart failurePatient Preference and Adherence, 2018
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Thirst in Heart Failure: A Systematic Literature ReviewEuropean Journal of Heart Failure, 2013
- A Randomized Controlled Pilot Study of Outcomes of Strict Allowance of Fluid Therapy in Hyponatremic Heart Failure (SALT-HF)Journal of Cardiac Failure, 2013
- Description of self‐reported fluid intake and its effects on body weight, symptoms, quality of life and physical capacity in patients with stable chronic heart failureJournal of Clinical Nursing, 2008